Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,772 across all filing types
Latest filing 2024-11-06 Interim / Quarterly Rep…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Q3 statement / Q3 financial report 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Statement first nine months' and provides detailed financial performance, segment analysis (Shared R&D and Just-Evotec Biologics), cash flow statements, and balance sheet data for the period ending 30 September 2024. It contains substantive financial statements and management analysis, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-06 English
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
M&A Activity Classification · 1% confidence The document is a news release dated November 5, 2024, announcing a significant corporate transaction: the sale of Evotec's API manufacturing facility to Monacum Partners. It details the strategic rationale ('Priority Reset' initiative) and the outcome of the divestiture. This type of announcement, which details a major corporate action (like a divestiture or M&A activity), is typically classified under M&A Activity (TAR) if it were a proposal or bid, or under Capital/Financing Update (CAP) if it were purely about fundraising. However, the core event is the sale/divestiture of a business unit, which often falls under M&A Activity (TAR) or, if it's a general corporate announcement not fitting other specific categories, it might default to Regulatory Filings (RNS). Since the definitions provided do not have a specific 'Divestiture' or 'Corporate Transaction' code, and this is a definitive announcement of a sale, it is most closely related to M&A Activity (TAR). Given the context of corporate actions, TAR is the best fit among the provided options for a sale/divestiture announcement, although it is not a takeover bid. If TAR is strictly for takeovers, the next best fit is RNS as a general regulatory announcement, but TAR captures the nature of the transaction better than RNS or CAP.
2024-11-05 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') by a legal entity (T. Rowe Price Group, Inc.) in Evotec SE, referencing specific German securities law articles (Article 40, Section 1 of the WpHG). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds. The code for Major Shareholding Notification is MRQ.
2024-11-01 English
Evotec SE to announce results for the first nine months 2024 on 06 November 2024
Report Publication Announcement Classification · 1% confidence The document is a short news release dated October 30, 2024, announcing that Evotec SE will release its financial results for the first nine months of 2024 on November 6, 2024. It also mentions details for an accompanying conference call/webcast. Since the document is an announcement about the future publication of financial results (which would typically be an IR or ER), and it is short, it fits the definition of a Report Publication Announcement (RPA). It is not the actual financial report itself, nor is it a full transcript or an earnings release containing the results.
2024-10-30 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly contains a section labeled 'Notification of Major Holdings'. It details changes in voting rights percentages (e.g., from 9.35% to 6.72%) held by a legal entity (T. Rowe Price Group, Inc.) in Evotec SE, referencing specific German securities law articles (WpHG). This content directly corresponds to the definition of a major shareholding notification, which is classified under the code MRQ (Major Shareholding Notification). Although it is a regulatory announcement, MRQ is more specific than the general RNS fallback.
2024-10-23 English
Evotec and Bristol Myers Squibb expand proteomics partnership
Regulatory Filings Classification · 1% confidence The document is a news release dated October 23, 2024, announcing an expansion of a partnership between Evotec and Bristol Myers Squibb regarding proteomics and molecular glue degraders. It details a US$ 50 million payment received by Evotec and discusses future potential milestones. This type of announcement, which communicates a significant business development, partnership update, or material event that is not a standard periodic financial report (like 10-K or IR), typically falls under general regulatory news or corporate announcements. Since it is not a formal Earnings Release (ER) which focuses only on financial figures, nor a specific filing like DIRS, DIV, or CAP, the most appropriate general category for a significant, non-standard corporate update distributed via a news service (EQS-News) is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements not covered by other specific codes. The document length is substantial (9770 chars), so it is not an RPA.
2024-10-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.